Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-384 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABT-384 | EXPERIMENTAL | - |
| Low dose ABT-384 | EXPERIMENTAL | - |
| Mid dose ABT-384 | EXPERIMENTAL | - |
| High dose ABT-384 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-384 | DRUG | Doses will be administered daily for 5 days. |
| Matching placebo to ABT-384 | DRUG | Doses will be administered daily for 21 days |
Inclusion Criteria: * Age is between 18 and 55 years * Judged to be in a condition of general good health based on the results of medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG Exclusion Criteria: * Use of protocol-prohibited medications within 2 weeks pr...
ABT-384 is an investigational small molecule being developed by Abbott Laboratories. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, including elderly subjects, to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
ABT-384 is being studied for use in healthy volunteers. It has not been approved for any medical condition. The clinical trials focus on evaluating the drug's safety, tolerability, and how it behaves in the body, rather than treating a specific disease.
ABT-384 is being developed by Abbott Laboratories, a company traded under the ticker symbol ABT. The drug is currently in Phase 1 clinical trials, which are being conducted in the United States.
ABT-384 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, involving a total of 40 healthy participants.
ABT-384 has two completed Phase 1 trials. NCT00968422 studied the drug in elderly subjects, enrolling 28 participants. NCT01009216 measured drug levels and pharmacodynamic activity in cerebrospinal fluid, enrolling 12 male participants. Both trials were conducted in the United States.
ABT-384 is the only name provided for this drug. No alternative names have been associated with it in the available information. It is a distinct investigational compound developed by Abbott Laboratories.